In its annual 10-K filing with the Securities and Exchange Commission (SEC), the platform disclosed that it is the subject of an SEC investigation regarding its public statements and disclosures regarding compounded semaglutide and related business relationships. On February 6, 2026, FDA stated its intent to take action against non-FDA-approved GLP-1 drugs being mass-marketed as alternatives to approved products
2020 Jul;21(7):363-83
Lovshin JA, Barnie A, DeAlmeida A, et al
Contact us for more information, or schedule your online consultation
Examining GHS-R1a constitutive activity, receptor desensitisation and resensitisation kinetics, and the pharmacological consequences of selective GHS-R1a activation in peripheral tissues including cardiac, hepatic, and immune cell models where distinguishing GHS-R1a-specific from prolactin and cortisol-mediated biology is critical for mechanistic interpretation
But its worth kind of taking a step back, both for perspective and back in time
